$0.45
2.38%
Downside
Day's Volatility :7.01%
Upside
4.74%
0.67%
Downside
52 Weeks Volatility :92.23%
Upside
92.17%
Period | Turnstone Biologics Corp. | Index (Russel 2000) |
---|---|---|
3 Months | -80.32% | 0.0% |
6 Months | -87.09% | 0.0% |
1 Year | -86.35% | 0.0% |
3 Years | -95.71% | -20.8% |
Market Capitalization | 10.7M |
Book Value | $2.58 |
Earnings Per Share (EPS) | -3.23 |
Wall Street Target Price | 6.58 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -66.1% |
Return On Equity TTM | -134.46% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 71.1M |
EBITDA | -77.8M |
Diluted Eps TTM | -3.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.9 |
EPS Estimate Next Year | -2.48 |
EPS Estimate Current Quarter | -0.93 |
EPS Estimate Next Quarter | -0.81 |
What analysts predicted
Upside of 1362.22%
Sell
Neutral
Buy
Turnstone Biologics Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Turnstone Biologics Corp. | -29.06% | -87.09% | -86.35% | -95.71% | -95.71% |
Regeneron Pharmaceuticals, Inc. | -10.93% | 8.12% | 21.23% | 85.29% | 239.25% |
Novo Nordisk A/s | -9.85% | -6.35% | 25.79% | 137.8% | 353.05% |
Alnylam Pharmaceuticals, Inc. | 5.73% | 77.74% | 60.24% | 32.45% | 248.92% |
Vertex Pharmaceuticals Incorporated | -0.6% | 17.7% | 29.79% | 160.59% | 174.92% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Turnstone Biologics Corp. | NA | NA | NA | -3.9 | -1.34 | -0.66 | NA | 2.58 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.47 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Turnstone Biologics Corp. | Buy | $10.7M | -95.71% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 239.25% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 353.05% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 248.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.8B | 174.92% | 32.84 | -4.74% |
Insights on Turnstone Biologics Corp.
Revenue is up for the last 3 quarters, 10.22M → 19.30M (in $), with an average increase of 24.0% per quarter
Netprofit is down for the last 3 quarters, -16.45M → -21.30M (in $), with an average decrease of 13.9% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.2% return, outperforming this stock by 146.5%
Organization | Turnstone Biologics Corp. |
Employees | 82 |
CEO | Dr. Sammy J. Farah M.B.A., Ph.D. |
Industry | Miscellaneous |
Mohr Company Nav Etf
$0.45
-3.92%
Cnsmr Discret Alphadex Etf First Trust
$0.45
-3.92%
Pimco Etf Trust Pimco Mortgage-backed Securities Active Exchange-traded Fund
$0.45
-3.92%
Fuel Tech Inc
$0.45
-3.92%
Ishares Morningstar Small Growth Index Fund
$0.45
-3.92%
Kentucky First Federal Bancorp
$0.45
-3.92%
Pasithea Therapeutics Corp
$0.45
-3.92%
Ishares Intl Div Growth Etf
$0.45
-3.92%
Allianzim Us Large Cap Buffer10 Sep Etf
$0.45
-3.92%